Cell3TM Target: PanHemeOnc Panel

Cell3™ Target: PanHemeOnc Panel

Testing for myeloid and lymphoid malignancies needs to be fast

Successful treatment and improved prognosis of hematological cancer is directly impacted by the speed and efficacy of diagnosis.1

The complexity of hematological malignancies often means laboratories have to use an interrogative and iterative testing approach across multiple different platforms. Leveraging Cell3 Target NGS panels to detect all key variants allows laboratories to streamline their workflows into one single test advancing hemato-oncology patient care.

The Cell3 Target: PanHemeOnc panel, designed by WMRGL is available as a customer-led design for any lab also looking to streamline their lymphoid and myeloid workflows.

"Clearly, the most efficient approach [for myeloid and lymphoid testing] is to have, as far as possible, everything going down one streamlined pathway.”

A targeted NGS panel, that can detect SNVs, indels and CNVs in genes associated with both myeloid and lymphoid has huge advantages for Jo Mason’s team in West Midlands Regional Genomics Laboratory (WMRGL) in the reduction of turnaround times and cost burdens associated with multi-testing approaches.

Taking less than 10 hours, with less than 2 hours hands-on time, it is designed with multiple stop points to provide flexibility within laboratory processing. Library preparation can be run manually or automated up to 96 samples in a single run. Indexes are available for up to 384 samples to allow for flexible batch sizes and scalability across all Illumina benchtop sequencers.

Fast

Prepare NGS libraries in as little as one day

Streamlined

Reduce multiple testing strategies into one simple workflow.

Comprehensive

Comprehensive design enables the detection of clinically relevant variants across multiple regions associated with both myeloid and lymphoid neoplasia

Trusted

Customer led, Nonacus custom design collaboration with Joanne Mason, Head of Haemato-oncology, West Midlands Regional Genomics Laboratory

Proven

SNVs detected at Variant Allele Fractions (VAF) as low as 1%. Detection of challenging targets including FLT3-ITD

Benefits from straight forward, automatable protocols

The panel design covers variants in 134 genes (including SRY for gender ID only) and 13 key regions for CNVs*, as well as boosted FLT3 coverage, KMT2A including exons and introns 1-14, and whole gene deletion events†

* CNV coverage: CNV del(1p), CNV gain(1q), CNV (11q), CNV 13q14; del(17p), CNV del(17p), CN-LOH 6p, CEBPA, GATA2, RUNX1, TERC, TERT, trisomy12

Whole gene deletion events: CEBPA, GATA2, RUNX1, TERC, TERT

Complete coverage of key genes

All transcripts covered for all genes

Our Partners

About

the company embarked on a journey into the realm of Genomics. Since then, it has continuously evolved, presenting forward-looking and ingenious solutions in this field.

Email Address

Phone Number

Our Location

Cell3™ Target: PanHemeOnc Panel

Testing for myeloid and lymphoid malignancies needs to be fast

"Clearly, the most efficient approach [for myeloid and lymphoid testing] is to have, as far as possible, everything going down one streamlined pathway.”

Benefits from straight forward, automatable protocols

The panel design covers variants in 134 genes (including SRY for gender ID only) and 13 key regions for CNVs*, as well as boosted FLT3 coverage, KMT2A including exons and introns 1-14, and whole gene deletion events†

Complete coverage of key genes

All transcripts covered for all genes

Our Partners

About

Social Media

Quick Links

Support Links

Locations